Research progress and development potential of oncolytic vaccinia virus.
10.1097/CM9.0000000000003585
- Author:
Xinyu ZHANG
1
;
Jiangshan HE
1
;
Yiming SHAO
1
Author Information
1. Changping Laboratory, Beijing 102206, China.
- Publication Type:Review
- Keywords:
Clinical;
Oncolytic virotherapy;
Tumor therapies Immune response;
Vaccinia virus
- MeSH:
Vaccinia virus/physiology*;
Humans;
Oncolytic Virotherapy/methods*;
Oncolytic Viruses/physiology*;
Neoplasms/therapy*;
Animals
- From:
Chinese Medical Journal
2025;138(7):777-791
- CountryChina
- Language:English
-
Abstract:
Oncolytic virotherapy is a promising therapeutic approach treating tumors, where oncolytic viruses (OVs) can selectively infect and lyse tumor cells through replication, while also triggering long-lasting anti-tumor immune responses. Vaccinia virus (VV) has emerged as a leading candidate for use as an OV due to its broad cytophilicity and robust capacity to express exogenous genes. Consequently, oncolytic vaccinia virus (OVV) has entered clinical trials. This review provides an overview of the key strategies used in the development of OVV, summarizes the findings from clinical trials, and addresses the challenges that must be overcome in the advancement of OVV-based therapies. Furthermore, it explores potential future strategies for enhancing the development and clinical application of OVV, intending to improve tumor treatment outcomes. The review aims to facilitate the further development and clinical adoption of OVV, thereby advancing tumor therapies.
